Sumatriptan treatment for migraine in a health maintenance organization: Economic, humanistic, and clinical outcomes

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 190-204

  Cohen, Jeffrey A ^a,b,d   Beall, Donna ^c   Beck, Arne ^a   Rawlings, Julia ^a   Miller, David W ^e   Clements, Bill ^e   Pait, D Gayla ^e   Batenhorst, Alice ^e  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MONTANA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

Health care use; Health related quality of life; HMO; Migraine; Sumatriptan

Indexed keywords

AMITRIPTYLINE; BUTALBITAL; DICHLORALPHENAZONE; HYDROXYZINE EMBONATE; IBUPROFEN; ISOMETHEPTENE MUCATE; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; PROMETHAZINE; PROPRANOLOL; SEROTONIN 1 AGONIST; SUMATRIPTAN; VALPROIC ACID; VERAPAMIL;

ADULT; ANALGESIC ACTIVITY; ARTICLE; BACTERIAL GROWTH; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; GROWTH INHIBITION; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PAIN ASSESSMENT; PATIENT SATISFACTION; PRODUCTIVITY; QUALITY OF LIFE; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 0005176605     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88278-8     Document Type: Article

References (33)

1. 1. Lipton TB, Stewart WF. Migraine in the United States: A review of epidemiology and health care use. Neurology. 1993;43 (Suppl 3):S6-S10.
2. 2. Smith R. Management of chronic headache. Can Fam Phys. 1989;35:1835-1839.
3. 3. Solomon GD. Quality-of-life assessment in patients with headache. PharmacoEconomics. 1994;6:34-41.
4. 4. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34:337-343.
5. 5. Stang PE, Osterhaus JT. Impact of migraine in the United States: Data from the National Health Interview Survey. Headache. 1993;33:29-35.
6. 6. Pryse-Phillips W, Findlay H, Tugwell P, et al. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333-339.
7. 7. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource use and lost labor costs of migraine headache in the United States. PharmacoEconomics. 1992;2:67-76.
8. 8. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. PharmacoEconomics. 1994;28:659-664.
9. 9. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the Medical Outcomes Study instrument. Headache. 1994;34:143-147.
10. 10. Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology. 1995;45(Suppl):5-9.
11. 11. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology. 1995;45(Suppl):10-14.
12. 12. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. NEJM. 1991; 325:316-321.
13. 13. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: Results of two clinical studies. Neurology. 1997;49:1225-1230.
14. 14. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the acute treatment of migraine: Effects on health-related quality of life, impact on health care resource use, and clinical efficacy. Fam Med. 1996;28:171-177.
15. 15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8:1-96.
16. 16. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: New England Medical Center, 1993.
17. 17. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care. 1992;30:473-483.
18. 18. Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1997;38:295-302.
19. 19. Jhingran P, Davis SM, LaVange LM, et al. Migraine-Specific Quality-of-Life. Questionnaire: Further investigation of the factor structure. PharmacoEconomics. 1998; 13:707-717.
20. 20. Miller DW, Kirchdoerfer LJ, Shepherd MD, et al. A disease-specific instrument to measure quality of life effects attributable to migraine. Presented at: the Health Services Research Association 10th Annual Meeting, Washington, DC, June 27-29, 1993. Poster.
21. 21. Mushet GR, Miller DW, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache. 1996;36:137-143.
22. 22. Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life associated with the use of sumatriptan to treat migraine. J Fam Pract. 1996;42:36-42.
23. 23. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health-Syst Pharm. 1996;53:633-638.
24. 24. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated health care costs. Am J Man Care. 1996;2:139-143.
25. 25. Legg RF, Sclar DA, Nemec NL, et al. Cost effectiveness of sumatriptan in a managed care population. Am J Man Care. 1997; 3:117-122.
26. 26. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache. 1995;35:449-454.
27. 27. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
28. 28. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial. Neurology. 1997;48:A121. Abstract.
29. 29. Legg RF, Sclar DA, Nemec NL, et al. Cost benefit of sumatriptan to an employer. Occup Environ Med. 1997;39:652-657.
30. 30. Pini LA, Sternieri E, Fabbri L, et al. High efficacy and low frequency of headache recurrence after oral sumatriptan. J Int Med Res. 1995;23:96-105.
31. 31. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology. 1995;45:1505-1509.
32. 32. Sheftell F, Watson C, Pait DG, et al. Low headache recurrence with naratriptan: Clinical parameters related to recurrence. Headache. 1998;38:405. Abstract.
33. 33. de Lissovoy G, Lazarus SS. The economic cost of migraine: Present state of knowledge. Neurology. 1994;44(Suppl 4):S56-S62.